Furthermore, PTGS2 protein (COX-2, HUGO Gene Nomenclature Committee (HGNC): 9605) has been well studied as a mediator of CRC, with high expression noted in approximately 50% of adenomas and 85% of adenocarcinomas [4, 5] and is well correlated with poor patient prognosis [6, 7]. This evidence concerns the gene PTGS2 and adenocarcinoma.